L'Oreal Earnings Rise on Growth Outside of China — Update
By David Sachs
L'Oreal's earnings rose in the second quarter, driven by growth outside of China.
On year, sales rose 5.3% on a like for like basis to 10.875 billion euros ($11.77 billion), the French cosmetics company said Tuesday after European markets closed.
Analysts expected sales of EUR10.78 billion, according to the Visible Alpha consensus.
Skin products drove growth, said the company behind Garnier and Lancome Paris. But the dermatological beauty category significantly missed expectations, RBC analysts said in a note.
Regionally, L'Oreal's emerging markets, Europe and North America drove growth, partially offsetting a decline in the Chinese market marked by soft consumer spending due to a sluggish economy.
The company posted a 2.4% decline in its North Asia region, including China. L'Oreal had aimed to reduce its reliance on the all-important market.
For the first half, L'Oreal's operating profit--a closely watched metric by analysts and traders--jumped 8% in the second quarter to EUR4.60 billion. Analysts expected operating profit at EUR4.57 billion, according to Visible Alpha. The operating margin hit 20.8% in the second half of last year.
The Paris-based company said it still aims to outperform the market this year.
Write to David Sachs at david.sachs@wsj.com
(END) Dow Jones Newswires
July 30, 2024 13:16 ET (17:16 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
What’s the Difference Between the CPI and PCE Indexes?
-
Micron Earnings: Great Guidance but Stock Now Looks Fairly Valued
-
August PCE Report Forecasts Show More Good News on Inflation
-
AI Stocks May Be Down, but Don’t Count Them Out
-
4 Stocks to Buy as the Fed Cuts Interest Rates
-
Markets Brief: The Uncertain Path to Neutral Interest Rates
-
What’s Happening in the Markets This Week
-
Where Top Stock Fund Managers Are Looking Next After the Fed Rate Cut
-
Our Top Pick for Investing in US Renewable Energy
-
How to Measure a Stock’s Uncertainty
-
How to Determine Whether a Stock Is Cheap, Expensive, or Fairly Valued
-
Why a Company’s Management and Capital Allocation Matter
-
How to Determine What a Stock Is Worth
-
How to Measure a Company’s Competitive Advantage
-
How to Think Like a Stock Analyst
-
How GLP-1 Drugs Like Ozempic Are Boosting Biopharma Stocks